Pan-cancer analysis identifies AL365181.3 as a novel prognostic biomarker for lung adenocarcinoma

Abstract

Abstract As a lncRNA, AL365181.3 is aberrantly expressed in multiple cancer types, including lung adenocarcinoma (LUAD). However, the biological process underlying the ability of AL365181.3 to promote the progression of LUAD is unclear. Here, the pancancer expression level of AL365181.3 was analyzed using the TCGA and GTEx databases, as well as its clinical characteristics and prognostic value. Finally, the in vitro and in vivo biological functions of AL365181.3 in LUAD were revealed by using various functional assays. We found that AL365181.3 was significantly more highly expressed in many types of cancer tissues, including LUAD tissues, than in adjacent normal tissues. LUAD patients with high AL365181.3 expression had poor prognoses. Functional enrichment analyses indicated that AL365181.3 is involved in the regulation of metabolism, MAPK signaling and other tumor regulatory signaling pathways.Finally, we found that knockdown of AL365181.3 reduced the proliferation and migratory capacity of LUAD cells, and knockdown of AL365181.3 resulted in a reduced in vivo tumorigenic capacity of LUAD cells. These findings provide a comprehensive understanding of the role of AL365181.3 in LUAD.